CXCR6/CXCL16 functions as a regulator in metastasis and progression of cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1806, Issue 1, 2010, Pages 42-49

  Deng, Ling ^a   Chen, Nianyong ^a   Li, Yan ^a   Zheng, Hong ^a   Lei, Qianqian ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cancer; CXCL16; CXCR6; Invasiveness; Metastasis

Indexed keywords

ADAM10 ENDOPEPTIDASE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CX3CL1; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR6; CXCL16 CHEMOKINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CELL PROLIFERATION; COLORECTAL CANCER; CYTOKINE RELEASE; HUMAN; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; METASTASIS; NASOPHARYNX CANCER; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR VASCULARIZATION; UPREGULATION;

ANIMALS; CHEMOKINE CX3CL1; CHEMOKINES, CXC; DISEASE PROGRESSION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM METASTASIS; NEOPLASMS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CHEMOKINE; RECEPTORS, SCAVENGER; RECEPTORS, VIRUS; SIGNAL TRANSDUCTION;

EID: 77953715955     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2010.01.004     Document Type: Review

References (80)

1. Al-Mehdi A.B., Tozawa K., Fisher A.B., Shientag L., Lee A., Muschel R.J. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat. Med. 2000, 6:100-102.
2. Hart I.R., Fidler I.J. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res. 1980, 40:2281-2287.
3. Zlotnik A. Chemokines and cancer. Int. J. Cancer 2006, 119:2026-2029.
4. Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer 2004, 4:540-550.
5. Kulbe H., Levinson N.R., Balkill F., Wilson J.L. The chemokine network in cancer-much more than directing cell movement. Int. J. Dev. Biol. 2004, 48:489-496.
6. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 1998, 338:436-445.
7. Struyf S., Proost P., Van Damme J. Regulation of the immune response by the interaction of chemokines and proteases. Adv. Immunol. 2003, 81:1-44.
8. Kucia M., Reca R., Miekus K., Wanzeck J., Wojakowski W., Janowska-Wieczorek A. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005, 23:879-894.
9. Andre F., Cabioglu N., Assi H., Sabourin J.C., Delaloge S., Sahin A., Broglio K., Spano J.P., Combadiere C., Bucana C., Soria J.C., Cristofanilli M. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann. Oncol. 2006, 17:945-951.
10. Zeelenberg I.S., Ruuls-Van Stalle L., Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res. 2003, 63:3833-3839.
11. Philips R.J., Burdick M.D., Lutz M., Belperio J.A., Keane M.P., Strieter R.M. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am. J. Respir. Crit. Care Med. 2003, 167:1676-1686.
12. Gardones A.R., Murakami T., Hwang S.T. CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via β1 integrin. Cancer Res. 2003, 63:6751-6757.
13. Sehgal A., Keener C., Boynton A.L., Warrick J., Murphy G.P. CXCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. J. Surg. Oncol. 1998, 69:99-104.
14. Burns J., Summers B., Wang Y., Melikian A., Berahocich R., Miao Z., Penfold M.E., Sunshine M.J., Littman D.R., Kuo C.J., Wei K., McMaster B.E., Wright K., Howard M.C., Schall T.J. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 2006, 203:2201-2213.
15. Wang J., Shiozawa Y., Wang J., Wang Y., Jung Y.H., Pienta K.J., Mehra R., Loberg R., Taichman R.S. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J. Biol. Chem. 2008, 283:4283-4294.
16. Liao F., Alkhatib G., Peden K., Sharma G., Berger E., Farber J. STRL33, a novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J. Exp. Med. 1997, 185:2015-2023.
17. Kim C.H., Kunkel E.J., Boisvert J., Johnston B., Campbell J.J., Genovese M.C., Greenberg H.B., Butcher E.C. Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. J. Clin. Invest. 2001, 107:595-601.
18. Kim C.H., Johnston B., Butcher E.C. Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24+Vbeta 11+NKT cell subsets with distinct cytokine-producing capacity. Blood 2002, 100:11-16.
19. Unutmaz D., Xiang W., Sunshine M.J., Campbell J., Butcher E., Littman D.R. The primate lentiviral receptor Bonzo/STRL33 is coordinately regulated with CCR5 and its expression pattern is conserved between human and mouse. J. Immunol. 2000, 165:3284-3292.
20. Nakayama T., Hieshima K., Izawa D., Tatsumi Y., Kanamaru A., Yoshie O. Profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J. Immunol. 2003, 170:1136-1140.
21. Heydtmann M., Lalor P., Eksteen J.A., Hubscher S., Briskin M., Adams D. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J. Immunol. 2005, 174:1055-1062.
22. Sato T., Thorlacius H., Johnston B., Staton T.L., Xiang W.K., Littman D.R., Butcher E.C. Role for CXCR6 in Recruitment of Activated CD8+ Lymphocytes to Inflamed Liver. J. Immunol. 2005, 174:277-283.
23. Nanki T., Shimaoka T., Hayashida K., Taniguchi K., Onehara S., Miyasaka N. Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis. Arthritis Rheum. 2005, 52:3004-3014.
24. van der Voort R., van Lieshout A.W., Toonen L.W., Sloetjes A.W., van den Berg W.B., Figdor C.G., Radstake T.R., Adema G.J. Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints. Arthritis Rheum. 2005, 52:1381-1391.
25. Agostini C., Cabrelle A., Calabrese F., Bortoli M., Scquizzato E., Carraro S., Miorin M., Beghè B., Trentin L., Zambello R., Facco M., Semenzato G. Role for CXCR6 and its ligand CXCL16 in the pathogenesis of T-cell alveolitis in sarcoidosis. Am. J. Respir. Crit. Care Med. 2005, 172:1290-1298.
26. Geissmann F., Cameron T.O., Sidobre S., Manlongat N., Kronenberg M., Briskin M.J., Dustin M.L., Littman D.R. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol. 2005, 3:e113.
27. Matloubian M., David A., Engel S., Ryan J.E., Cyster J.G. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat. Immunol. 2000, 1:298-304.
28. Wilbanks A., Zondlo S.C., Murphy K., Mak S., Soler D., Langdon P., Andrew D.P., Wu L.J., Briskin M. Expression cloning of the STRL33/BONZO/TYMSTR ligand reveals elements of CC, CXC, and CX3C chemokines. J. Immunol. 2001, 166:5145-5154.
29. Shimaoka T., Kume N., Minami M., Hayashida K., Kataoka H., Kita T., Yoneharaet S. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J. Biol. Chem. 2000, 275:40663-40666.
30. Gutwein P., Schramme A., Sinke N., Abdel-Bakky M.S., Voss B., Obermüller N., Doberstein K., Koziolek M., Fritzsche F., Johannsen M., Jung K., Schaider M., Altevogt P., Ludwig A., Pfeilschifter J., Kristiansen G. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur. J. Cancer. 2008, 10:1016-1023.
31. Gough P.J., Garton K.J., Wille P.T., Rychlewski M., Dempsey P.J., Raines E.W. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J. Immunol. 2004, 172:3678-3685.
32. Abel S., Hundhausen C., Mentlein R., Schulte A., Berkhout T.A., Broadway N., Hartmann D., Sedlacek R., Dietrich S., Muetze B., Schuster B., Kallen K.J., Saftig P., Rose-John S., Ludwig A. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J. Immunol. 2004, 172:6362-6372.
33. Ludwig A., Hundhausen C., Lambert M.H., Broadway N., Andrews R.C., Bickett D.M., Leesnitzer M.A., Becherer J.D. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb. Chem. High Throughput Screen. 2005, 8:161-171.
34. Motsinger A., Haas D.W., Stanic A.K., Van Kaer L., Joyce S., Unutmaz D. CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J. Exp. Med. 2002, 195:869-879.
35. Zhuge X., Murayama T., Arai H. CXCL16 is a novel angiogenic factor for human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 2005, 331:1295-1300.
36. Lu Y., Wang J., Xu Y., Koch A.E., Cai Z., Chen X., Galson D.L., Taichman R.S., Zhang J. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol. Cancer Res. 2008, 6:546-554.
37. Wang J., Lu Y., Wang J., Koch A.E., Zhang J., Taichman R.S. CXCR6 induces prostate cancer progression by the AKT/Mammalian target of rapamycin signaling pathway. Cancer Res. 2008, 68:10367-10376.
38. Darash-Yahana M., Gillespie J.W., Hewitt S.M., Chen Y.K., Maeda S., Stein I., Singh S.P., Bedolla R.B., Peled A., Troyer D.A., Pikarsky E., Karin M., Farber J.M. The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. Plos One 2009, 4:e6695.
39. Meijer J., Ogink J., Kreike B., Nuyten D., de Visser K.E., Roos E. The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation. Cancer Res. 2008, 68:4701-4708.
40. Lin S., Sun L., Hu J.L., Wan S.Y., Zhao R.P., Yuan S.T., Zhang L.Y. Chemokine C-X-C motif receptor 6 contributes to cell migration during hypoxia. Cancer Lett. 2009, 279:108-117.
41. Hojo S., Koizumi K., Tsuneyama K., Arita Y., Cui Z.G., Shinohara K., Minami T., Hashimoto I., Nakayama T., Sakurai H., Takano Y., Yoshie O., Tsukada K., Saiki K.I. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res. 2007, 67:4725-4731.
42. Wagsater D., Hugander A., Dimberg J. Expression of CXCL16 in human rectal cancer. Int. J. Mol. Med. 2004, 14:65-69.
43. Gaida M.N., Mayer C. Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma. Int. J. Oncol. 2008, 33:297-308.
44. Gaida M.M., Günther F., Wagner C., Friess H., Giese N.A., Schmidt J., Hänsch G.M., Wente M.N. Expression of the CXCR6 on polymorphonuclear neutrophils in pancreatic carcinoma and in acute, localized bacterial infections. Clin. Exp. Immunol. 2008, 154:216-223.
45. Ou D.L., Chen C.L., Lin S.B., Hsu C.H., Lin L.I. Chemokine receptor expression profiles in nasopharyngeal carcinoma and their association with metastasis and radiotherapy. J. Pathol. 2006, 210:363-373.
46. Held-Feindt J., Rehmke J.B., Mentlein R., Hattermann K., Knerlich F., Hugo H.H., Ludwig A., Mehdorn H.M. Overexpression of CXCL16 and its receptor CXCR6/Bonzo promotes growth of human schwannomas. Glia 2008, 56:764-774.
47. Seidl H., Richtig E., Tilz H., Stefan M., Schmidbauer U., Asslaber M., Zatloukal K., Herlyn M., Schaider H. Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma. Human Pathol. 2007, 38:768-780.
48. Belperio J.A., Keane M.P., Arenberg D.A., Addison C.L., Ehlert J.E., Burdick M.D., Strieter R.M. CXC chemokines in angiogenesis. J. Leukoc. Biol. 2000, 68:1-8.
49. Naito Y., Saito K., Shiiba K., Ohuchi A., Saigenji K., Nagura H., Ohtani H. CD8+T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998, 58:3491-3494.
50. Ropponen K.M., Eskelinen M.J., Lipponen P.K., Alhava E., Kosma V.M. Prognostic value of tumor-infiltrating lymphocytes (TILs) in colorectal cancer. J. Pathol. 1997, 182:318-324.
51. Matsumura S., Wang B.M., Kawashima N., Braunstein S., Badura M., Cameron T.O., Babb J.S., Schneider R.J., Formenti S.C., Dustin M.L., Demaria S. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J. Immunol. 2008, 181:3099-3107.
52. Phillips R.J., Mestas J., Gharaee-Kermani M., Burdick M.D., Sica A., Belperio J.A., Keane M.P., Strieter R.M. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1α. J. Biol. Chem. 2005, 280:22473-22481.
53. Wang J., Wang J., Sun Y., Song W., Nor J.E., Wang C.Y., Taichman R.S. Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell. Signal. 2005, 17:1578-1592.
54. Sun Y.X., Wang J., Shelburne C.E., Lopatin D.E., Chinnaiyan A.M., Rubin M.A., Pienta K.J., Taichman R.S. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J. Cell. Biochem. 2003, 89:462-473.
55. Hu W., Zhen X., Xiong B., Wang B., Zhang W., Zhou W. CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells. Cancer Sci. 2008, 99:1362-1369.
56. Ottaiano A., di Palma A., Napolitano M., Pisano C., Pignata S., Tatangelo F., Botti G., Acquaviva A.M., Castello G., Ascierto P.A., Iaffaioli R.V., Scala S. Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. Cancer Immunol. Immunother. 2005, 14:781-791.
57. Ottaiano A., Franco R., Aiello-Talamanca A., Liguori G., Tatangelo F., Delrio P., Nasti G., Barletta E., Facchini G., Daniele B., Di-Blasi A., Napolitano M., Ierano C., Calemma R., Leonardi E., Albino V., De-Angelis V., Falanga M., Boccia V., Capuozzo M., Parisi V. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin. Cancer Res. 2006, 12:2795-2803.
58. Kim J., Takeuchi H., Lam S.T., Turner R.R., Wang H.J., Kuo C., Foshag L., Bilchik A.J., Hoon D.S. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J. Clin. Oncol. 2005, 23:1743-1750.
59. Marchesi F., Monti P., Leone B.E., Zerbi A., Vecchi A., Piemonti A., Mantovani A., Allavena A. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res. 2004, 64:8420-8427.
60. Koshiba T., Hosotani R., Miyamoto Y., Ida J., Tsuji S. Expression of stromal cell-derived factor I and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin. Cancer Res. 2000, 6:3530-3535.
61. Schrader A.J., Lechner O., Templin M., Dittmar K.E., Machtens S., Mengel M., Probst-Kepper M., Franzke A., Wollensak T., Gatzlaff P., Atzpodien J., Buer J., Lauber J. CXCR4/CXCL12 expression and signaling in kidney cancer. Br. J. Cancer 2002, 86:1250-1256.
62. Staller P., Sulitkova J., Lisztwan J., Monch H., Oakeley E.J., Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumor suppressor pVHL. Nature 2002, 425:1250-1256.
63. Taichman R.S., Cooper C., Keller E.T., Pienta K.J., Taichman N.S., McCauley L.K. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002, 62:1832-1837.
64. Mochizuki H., Matsubara A., Teishima J., Mutaguchi K., Yasumoto H., Dahiya R., Usui T., Kamiya K. Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis. Biochem. Biophys. Res. Commun. 2004, 320:656-663.
65. Akashi T., Koizumi K., Tsuneyama K., Saiki I., Takano Y., Fuse H. Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci. 2008, 86:539-542.
66. Hu J., Deng X., Bian X., Li G., Tong Y., Li Y., Wang Q., Xin R., He X., Zhou G., Xie P., Li Y., Wang J.M., Cao Y. The expression of functional chemokine receptor CXCR4 is associated with the metastatic potential of human nasopharyngeal carcinoma. Clin. Cancer Res. 2005, 11:4658-4665.
67. Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., Greaves D.R., Zlotnik A., Schall T.J. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997, 385:640-644.
68. Fong A.M., Robinson L.A., Steeber D.A., Tedder T.F., Yoshie O., Imai T., Patel D.D. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J. Exp. Med. 1998, 188:1413-1419.
69. Verge G.M., Milligan E.D., Maier S.F., Watkins L.R., Naeve G.S., Foster A.C. Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur. J. Neurosci. 2004, 20:1150-1160.
70. Dichmann S., Herouy Y., Purlis D., Rheinen H., Gebicke-Harter P., Norgauer J. Fractalkine induces chemotaxis and actin polymerization in human dentritic cells. Inflamm. Res. 2001, 50:529-533.
71. Ohta M., Tanaka F., Yamaguchi H., Sadanaga N., Inoue H., Mori M. The high expression of fractalkine results in a better prognosis for colorectal cancer patients. Int. J. Oncol. 2005, 26:41-47.
72. Hyakudomi M., Matsubara T., Hyakudomi R., Yamamoto T., Kinugasa S., Yamanoi A., Maruyama R., Tanaka T. Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma. Ann. Surg. Oncol. 2008, 15:1775-1782.
73. Tang L., Hu H.D., Hu P., Lan Y.H., Peng M.L., Chen M., Ren H. Gene therapy with CX3CL1/fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma. Gene Ther. 2007, 14:1226-1234.
74. Guo J., Wang B., Zhang M., Chen T., Yu Y., Regulier E., Homann H.E., Qin Z., Ju D.W., Cao X. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther. 2002, 9:793-803.
75. Ren T., Chen Q., Tian Z., Wei H. Down-regulation of surface fractalkine by RNA interference in B16 melanoma reduced tumor growth in mice. Biochem. Biophys. Res. Commun. 2007, 364:978-984.
76. Marchesi F., Piemonti L., Fedele G., Destro A., Roncalli M., Albarello L., Doglioni C., Anselmo A., Doni A., Bianchi P., Laghi L., Malesci A., Cervo L., Malosio M., Reni M., Zerbi A., Di Carlo V., Mantovani A., Allavena P. The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res. 2008, 68:9060-9069.
77. Jamieson W.L., Shimizu S., D'Ambrosio J.A., Meucci O., Fatatic A. CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008, 68:1715-1722.
78. Shulby S.A., Dolloff N.G., Stearns M.E., Meucci O., Fatatis A. CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res. 2004, 64:4693-4698.
79. Easton J.B., Houghton P.J. Therapeutic potential of target of rapamycin inhibitors. Expert Opin. Ther. Targets 2004, 8:551-564.
80. Vignot S., Faivre S., Aguirre D., Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 2005, 16:525-537.